INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

January 30, 2024

https://www.globenewswire.com/news-release/2024/01/30/2819914/0/en/INmune-Bio-Announces-FDA-Removal-of-Clinical-Hold-for-Alzheimer-s-Disease-Program.html

The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final patient is enrolled.  

Read more at globenewswire.com

Related news for (INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.